1. Home
  2. DOLE vs TSHA Comparison

DOLE vs TSHA Comparison

Compare DOLE & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dole plc

DOLE

Dole plc

HOLD

Current Price

$16.16

Market Cap

1.4B

ML Signal

HOLD

Logo Taysha Gene Therapies Inc.

TSHA

Taysha Gene Therapies Inc.

HOLD

Current Price

$4.75

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DOLE
TSHA
Founded
1851
2019
Country
Ireland
United States
Employees
N/A
N/A
Industry
Farming/Seeds/Milling
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.5B
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
DOLE
TSHA
Price
$16.16
$4.75
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
$10.56
AVG Volume (30 Days)
645.8K
2.8M
Earning Date
02-25-2026
02-25-2026
Dividend Yield
2.11%
N/A
EPS Growth
N/A
N/A
EPS
0.15
N/A
Revenue
$8,974,210,000.00
$6,310,000.00
Revenue This Year
$9.28
N/A
Revenue Next Year
$1.84
N/A
P/E Ratio
$107.27
N/A
Revenue Growth
7.09
N/A
52 Week Low
$12.52
$1.05
52 Week High
$16.21
$6.02

Technical Indicators

Market Signals
Indicator
DOLE
TSHA
Relative Strength Index (RSI) 73.05 46.79
Support Level $15.29 $4.48
Resistance Level $15.75 $4.89
Average True Range (ATR) 0.33 0.28
MACD 0.12 -0.01
Stochastic Oscillator 90.03 43.50

Price Performance

Historical Comparison
DOLE
TSHA

About DOLE Dole plc

Dole PLC operates in the North American and European markets for fresh fruits and vegetables. The company's segment includes Fresh Fruit; Diversified Fresh Produce - EMEA; Diversified Fresh Produce - Americas and ROW. It generates maximum revenue from the Diversified Fresh Produce - EMEA segment. Diversified Fresh Produce - EMEA segment includes Dole's Irish, Dutch, Spanish, Portuguese, French, Italian, U.K., Swedish, Danish, South African, Eastern European, and Brazilian businesses, the majority of which sell a variety of imported and local fresh fruits and vegetables through retail, wholesale and, in some instances, food service channels across the European marketplace.

About TSHA Taysha Gene Therapies Inc.

Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.

Share on Social Networks: